Telomir Pharmaceuticals TELO Q4 2025 Earnings WiderthanExpected Loss Amid Ongoing Development RYAN Q1 2026 Earnings EPS Surpasses Estimates Amid Strong Specialty Insurance Demand VNO Q1 2026 Earnings EPS Misses Estimates as Office Sector Pressures Persist VLYPO Q1 2026 Earnings Slight EPS Beat Amid Stable Operations REYN Q1 2026 Earnings EPS Surprises to the Upside Stock Edges Higher GBFH Q1 2026 Earnings EPS Misses Estimates by Wide Margin as Stock Declines